Investor Relations

2013 Press Releases

Webcast ImageWebcast
Q4 2016 Lantheus Holdings, Inc. Earnings Conference Call (Replay)
02/21/17 at 4:30 p.m. ET
Q4 2016 Lantheus Holdings, Inc. Earnings Conference Call
Tuesday, February 21, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
11/06/13Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time
N. Billerica, Mass., November 6, 2013 – Lantheus Medical Imaging, Inc. ("Lantheus") today announced that it will host a conference call at 3:00 p.m. ET on Wednesday, November 13, 2013, to discuss its financial and operating results for the third quarter of 2013. To access the live conference call via telephone, please dial 1-877-280-4957 (U.S. callers) or 1 857-244-7314 (international callers) and provide passcode 97560845. A live audio webcast of the call also will be available on the homepa... 
10/29/13Lantheus Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease
N. BILLERICA, Mass. (October 29, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced preliminary results from the first of two planned Phase 3 trials to assess the diagnostic efficacy of flurpiridaz F 18, an imaging agent used in Positron Emission Tomography (PET) myocardial perfusion imaging (MPI) for the detection of coronary artery disease (CAD). The trial compared PET MPI with flurpiridaz ... 
09/10/13Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013
FOR IMMEDIATE RELEASE CONTACTS:     Lantheus Medical Imaging   Pure Communications Linda Lennox   Michele Rozen 978-671-8854   617-730-8284       Meara Murphy     978-671-8508                     Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19,... 
08/01/13Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time
FOR IMMEDIATE RELEASE CONTACTS: Linda Lennox 978-671-8854 Meara Murphy 978-671-8508 Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time N. Billerica, Mass., August 1, 2013 – Lantheus Medical Imaging, Inc. (“Lantheus”) today announced that it will host a conference call at 4:00 p.m. ET on Thursday, August 8, 2013, to discuss its financial and operating results for the second quarter of 2013. To access the live conference call v... 
07/11/13Lantheus Medical Imaging Announces Chief Financial Officer Transition
CONTACTS: Lantheus Medical Imaging   Pure Communications Linda Lennox   Michele Rozen Office: 978-671-8854   617-730-8284 Cell: 908-627-3424           Meara Murphy     Office: 978-671-8508     Cell: 617-794-1045                   FOR IMMEDIATE RELEASE  Lantheus Medical Imaging A... 
06/12/13Lantheus Medical Imaging to Present at Wells Fargo Securities 2013 Healthcare Conference
N. Billerica, Mass., June 12, 2013 – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that Jeff Bailey, President and Chief Executive Officer, will present at the Wells Fargo Securities 2013 Healthcare Conference in Boston. The presentation will take place on Wednesday, June 19, 2013, at 2:25 p.m., Eastern Time.  Mr. Bailey will provide a Company overview and business update. To access a live... 
05/29/13Lantheus Medical Imaging to Present at Jefferies 2013 Global Healthcare Conference
N. Billerica, Mass., May 29, 2013 – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that Jeff Bailey, President and Chief Executive Officer, will present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5, 2013, at 1:30 p.m., Eastern Time.  Mr. Bailey will provide a Company overview and business update. To access a live webcast of the presentation, please visit the Compa... 
05/07/13Lantheus Medical Imaging to Host First Quarter 2013 Conference Call on May 14, 2013 at 4:00 p.m. Eastern Time
N. Billerica, Mass., May 7, 2013 – Lantheus Medical Imaging, Inc. (“Lantheus”) today announced that it will host a conference call at 4:00 p.m. ET on Tuesday, May 14, 2013, to discuss its financial and operating results for the first quarter of 2013. To access the live conference call via telephone, please dial 1-877-415-3178 (U.S. callers) or 1-857-244-7321 (international callers) and provide passcode 30236878. A live audio webcast of the call also will be available on the homepage of the Comp... 
05/01/13Lantheus Medical Imaging to Proceed with Flurpiridaz F 18 Phase 3 Clinical Program Based on Interim Analysis of Data from First Phase 3 Study
No. BILLERICA, Mass. (May 1, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced an important milestone for its Phase 3 flurpiridaz F 18 clinical program. An interim analysis of the first of two Phase 3 studies has met the criteria for completion. “The interim analysis was an important achievement on the way to bringing this potentially game-changing agent to market,” said Jeff Bailey, Presi... 
04/29/13Lantheus Medical Imaging to Present Data on Novel PET Cardiac Imaging Agent Flurpiridaz F 18 at ICNC 11th Annual Meeting
N. BILLERICA, Mass. (April 29, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that data assessing the value of flurpiridaz F 18 myocardial standardized uptake value (SUV) analysis in the clinical assessment of intermediate to severe coronary stenosis will be presented in an oral presentation at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC) 11th Annual ... 
04/15/13Lantheus Medical Imaging Realigns Executive Leadership Team
Mary Anne Heino Joins Company as New Chief Commercial Officer; Company Positioned to Optimize Growth No. BILLERICA, Mass. (April 15, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the Company is realigning its executive management team to optimize growth of the organization. To infuse new talent into the Company, Mary Anne Heino has been appointed as the new Chief Commercial Office... 
03/28/13Lantheus Medical Imaging to Host Fourth Quarter 2012 Conference Call on April 2, 2013 at 4:00 p.m. Eastern Time
N. Billerica, Mass., March 28, 2013 – Lantheus Medical Imaging, Inc. (“Lantheus”) today announced that it will host a conference call at 4:00 p.m. ET on Tuesday, April 2, 2013, to discuss its financial and operating results for the fourth quarter and full year of 2012. To access the live conference call via telephone, please dial 1-800-299-9086 (U.S. callers) or 1-617-786-2903 (international callers) and provide passcode 66914033. A live audio webcast of the call also will be available on the h... 
03/21/13Lantheus Medical Imaging Focuses on Growth, Takes Steps to Reduce Expenses
No. BILLERICA, Mass. (March 21, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that under its new leadership team led by Jeff Bailey, President and Chief Executive Officer, the Company is taking steps to become more competitive and more focused on future growth. As the Company completes its first of two Phase 3 trials in its clinical development program, it will seek to engage one or more... 
03/19/13Lantheus Medical Imaging Announces Molybdenum-99 Supply Contract with Institute for Radioelements
Agreement Reinforces Lantheus’ Ongoing Commitment to Ensuring Reliable Access to Important Medical Isotope No. BILLERICA, Mass. (March 19, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced a new supply contract with the Institute for Radioelements (IRE) to receive a supply of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), for use in its TechneLite® (Technetium Tc 99m... 
03/06/13Lantheus Medical Imaging Announces Appointment of Cesare Orlandi, M.D., as New Chief Medical Officer
No. BILLERICA, Mass. (March 6, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the appointment of Cesare Orlandi, M.D., as the Company’s new Chief Medical Officer. Dr. Orlandi brings to the Company more than 20 years of diverse pharmaceutical industry experience with a proven track record of directing successful drug development programs, providing leadership in product pipeline portfolio ... 
02/11/13Lantheus Medical Imaging Announces FDA Approval of Jubilant HollisterStier
Important Advance in Supply Chain Diversification Strategy to Ensure Consistent, Reliable Supply of Key Products No. BILLERICA, Mass. (February 11, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a Supplemental New Drug Application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for... 
01/24/13Lantheus Medical Imaging Announces Appointment of Jeffrey A. Bailey as New Chief Executive Officer
Brian A. Markison Appointed as Chairman of Lantheus’ Board of Directors No. BILLERICA, Mass. (January 24, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the appointment of Jeffrey A. Bailey as the Company’s new President, Chief Executive Officer, and a member of the Board of Directors. Mr. Bailey replaces Donald Kiepert, who resigned from Lantheus to pursue other opportunities. Mr. Bai... 
01/09/13Lantheus Medical Imaging Introduces Low-Enriched Uranium (LEU) TechneLite® Generator
Supports Long-Term Strategy to Eliminate Use of Highly Enriched Uranium (HEU)-Produced Molybdenum and Technetium No. BILLERICA, Mass. (January 9, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that the Company has added a Low-Enriched Uranium (LEU) TechneLite® (Technetium Tc 99m Generator) generator to the Company’s nuclear imaging product portfolio. Lantheus’ LEU TechneLite® generat... 
01/03/13Lantheus Medical Imaging and FUJIFILM RI Pharma Renew Long-Term License and Distribution Agreement for Cardiolite and Neurolite in Japan
Agreement Extends Partnership in One of the Largest Imaging Agent Markets and Ensures Continued Access to Lantheus’ Radiopharmaceuticals for SPECT No. BILLERICA, Mass. (January 3, 2013) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that it has entered into a new agreement with FUJIFILM RI Pharma Co., Ltd. (FRI) to license and distribute Cardiolite® (Kit for the Preparation of Te...